Drugs / AGEN2017
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03673020 | May 2019 → Feb 2021 | cancer | Agenus Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGEN2017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673020 ↗ |
| Known as | ASV | “This is a Phase 1a study to evaluate neoantigen vaccine, AutoSynVax (ASV®) AGEN2017 in subjects with resected solid tumors, no evidence of disease (NED), and with an estimated...” NCT03673020 ↗ |
| Known as | AutoSynVax | “This is a Phase 1a study to evaluate neoantigen vaccine, AutoSynVax (ASV®) AGEN2017 in subjects with resected solid tumors, no evidence of disease (NED), and with an estimated...” NCT03673020 ↗ |
| Modality | Vaccine | “Neoantigen Vaccine” NCT03673020 ↗ |
| Route | Subcutaneous | “every two weeks subcutaneous injection of AGEN2017 + QS-21 adjuvant” NCT03673020 ↗ |